Develops fecal microbiota transplantation (FMT) for ulcerative colitis, cancers and Parkinson's, with a proprietary supply chain.
| Date | Round | Amount |
|---|---|---|
| Feb 2026 | Series B Metagen Therapeutics closed its Series B at 3.52 billion yen in total, with a 1.19 billion third close subscribed by CVCs of Aska, Canon MJ, Matsukiyo Cocokara and Medipal. | $22.9M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.